Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.

NCT00733616 is registered in ClinicalTrials.gov with Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) as lead sponsor.

NCT NCT00733616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.
Lead sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
May 31, 2012
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer